Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: A randomized controlled clinical trial

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

361

HTML

1091

Figures (1-2)

113

Tables (1-6)

138

Sum=1703

Feb 28, 2006 (publication date) through Apr 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Feb 28, 2006; 12(8): 1265-1269
Published online Feb 28, 2006. doi: 10.3748/wjg.v12.i8.1265

Table 6 Reasons for withdrawal from the study

Causes	Triple therapy group	Dual group therapy Causes Triple therapy group
Anemia	2	3	NS
Psychosomatic	3	4	NS
Anorexia & Fatigue	2	3	NS
HCC¹	1	0	NS
Dizziness	0	1	NS
Lost to follow-up	3	2	NS
Total	11	13	NS

Fisher’s exact test. NS, not significant.

¹Hepatocellular carcinoma was detected during the treatment.

Citation: Suzuki H, Takagi H, Sohara N, Kanda D, Kakizaki S, Sato K, Mori M. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: A randomized controlled clinical trial. World J Gastroenterol 2006; 12(8): 1265-1269
URL: https://www.wjgnet.com/1007-9327/full/v12/i8/1265.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i8.1265